Results 1 to 10 of about 1,610,894 (277)

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade [PDF]

open access: yesClinical and Translational Medicine, 2018
Immune checkpoint inhibitors have demonstrated broad single-agent antitumor activity and a favorable safety profile that render them attractive agents to combine with other systemic anticancer therapies.
Jun Gong   +7 more
doaj   +7 more sources

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma

open access: yesBiomedicines, 2022
Malignant pleural mesothelioma (MPM) is a fatal cancer type that affects the membranes lining the lungs, and is causally associated with asbestos exposure. Until recently, the first-line treatment consisted of a combination of chemotherapeutics that only
Sophie Rovers   +6 more
doaj   +2 more sources

Case Report: Durable remission in stage IV melanoma following strategic immune checkpoint inhibitor class rotation and rechallenge. [PDF]

open access: yesFront Oncol
Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in patients with regional and distant melanoma metastases. Severe immune-related adverse events (irAEs) occur in 20% (single agent) to nearly 50% (dual agents) of patients and may ...
Raja J   +6 more
europepmc   +2 more sources

Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden

open access: yesFrontiers in Oncology, 2023
Single-agent immune checkpoint blockade has shown no clinical benefits in pancreatic cancer. Recently, the programmed cell death protein 1 (PD-1) antibody pembrolizumab has been recommended as a treatment option for high tumor mutational burden (TMB ...
Mengyao Dai   +22 more
doaj   +1 more source

Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd–5th, 2020, Italy)

open access: yesJournal of Translational Medicine, 2021
Advances in immune checkpoint therapy and targeted therapy have led to improvement in overall survival for patients with advanced melanoma. Single agent checkpoint PD-1 blockade and combination with BRAF/MEK targeted therapy demonstrated benefit in ...
Paolo A. Ascierto   +22 more
doaj   +1 more source

The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy

open access: yesFrontiers in Cell and Developmental Biology, 2021
In the era of immune checkpoint blockade cancer therapy, cytokines have become an attractive immune therapeutics to increase response rates. Interleukin 21 (IL21) as a single agent has been evaluated for cancer treatment with good clinical efficacy ...
Shaoxian Wu   +11 more
doaj   +1 more source

The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials

open access: yesJournal of Hematology & Oncology, 2021
Several targeted therapies have shown efficacy in patients with advanced gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJC), including anti-angiogenic agents and immune checkpoint inhibitors. Ramucirumab, an anti-VEGFR2 antibody, has
Anwaar Saeed, Robin Park, Weijing Sun
doaj   +1 more source

Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors?

open access: yesClinical Medicine Insights: Oncology, 2020
Treatment of cancer has transformed with the introduction of checkpoint inhibitors. However, the majority of solid tumor patients do not respond to checkpoint blockade. In contrast, the response rate to programmed cell death 1 (PD-1) blockade in relapsed/
Ah-Reum Jeong   +2 more
doaj   +1 more source

Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer

open access: yesTherapeutic Advances in Medical Oncology, 2020
Immune checkpoint inhibitors targeting PD-1 and PD-L1 have demonstrated anti-tumor activity in several advanced solid malignancies. In previously treated metastatic castration resistant prostate cancer (mCRPC), a small subset of patients have a ...
Harry J. Han   +3 more
doaj   +1 more source

Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin)

open access: yesJCI Insight, 2021
Glioblastoma is a highly malignant brain tumor with no curative treatment options, and immune checkpoint blockade has not yet shown major impact. We hypothesized that drugs targeting mitosis might affect the tumor microenvironment and sensitize cancer ...
Vassilis Genoud   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy